Paper Details

  1. Home
  2. Paper Details

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era.

Author: BoslyAndre, BrièreJosette, GisselbrechtChristian, GlassBertram, HagbergHans, KettererNicolas, LinchDavid C, MaDavid, MoskowitzCraig H, MounierNicolas, SchmitzNorbert, ShpilbergOfer, Singh GillDevinder, TrnenyMarek

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Rituximab, ifosfamide, etoposide, and carboplatin (R-ICE) and rituximab, dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP) showed similar response rates in patients with relapsed diffuse large B-cell lymphoma. Early relapses after rituximab-containing first-line therapy had a poor prognosis, with no significant difference between R-ICE and R-DHAP.
Paper Details　
Original Abstract of the Article :
PURPOSE: Salvage chemotherapy followed by high-dose therapy and autologous stem-cell transplantation (ASCT) is the standard treatment for relapsed diffuse large B-cell lymphoma (DLBCL). Salvage regimens have never been compared; their efficacy in the rituximab era is unknown. PATIENTS AND METHODS: ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664033/

データ提供：米国国立医学図書館（NLM）

Relapsed Large B-Cell Lymphoma: Fighting Back with Salvage Regimens

Relapsed [diffuse large B-cell lymphoma (DLBCL)] is a challenging condition that requires aggressive treatment. This research compared two salvage regimens, [rituximab, ifosfamide, etoposide, and carboplatin (R-ICE)] and [rituximab, dexamethasone, high-dose cytarabine, and cisplatin (R-DHAP)], in patients with relapsed DLBCL. Both regimens demonstrated similar response rates, with no significant difference in [event-free survival (EFS)] or [overall survival]. However, the study identified factors that influenced outcomes, such as [time of relapse] and [prior rituximab treatment].

Salvage Regimens: Equally Effective but with Varying Prognoses

This study provides valuable insights into the management of relapsed DLBCL, demonstrating the effectiveness of both [R-ICE] and [R-DHAP] regimens. However, the study also highlights the importance of considering factors such as [time of relapse] and [prior rituximab treatment] when determining treatment strategies and predicting prognosis.

Individualized Treatment for Lymphoma

This study emphasizes the need for individualized treatment approaches for relapsed DLBCL. Understanding factors that influence treatment response and survival is crucial for tailoring therapies to each patient's unique needs and maximizing their chances of a positive outcome.

Dr.Camel's Conclusion

Fighting lymphoma is a tough battle, like traversing a scorching desert. This study provides valuable insights into the effectiveness of different treatment strategies, helping clinicians navigate the complexities of relapsed DLBCL and provide the best possible care for their patients.

Date :
  1. Date Completed 2010-10-18
  2. Date Revised 2023-10-25
Further Info :

Pubmed ID

20660832

DOI: Digital Object Identifier

PMC3664033

Related Literature

Article Analysis
・Effective treatment of lymphoma
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.